National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Alemtuzumab

Synonyms

ALEMTUZUMAB

alemtuzumab

Alemtuzumab

Campath

Campath-1H

LDP-03

LDP03

Lemtrada

MabCampath

Definitions

A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1681

Accepted_Therapeutic_Use_For

Chronic Lymphocytic Leukemia (CLL)

ALT_DEFINITION

A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.

CAS_Registry

216503-57-0

code

C1681

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

Contributing_Source

CTRP

FDA

GDC

HemOnc

DEFINITION

A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)

Display_Name

Alemtuzumab

FDA_UNII_Code

3A189DH42V

FULL_SYN

ALEMTUZUMAB

alemtuzumab

Alemtuzumab

Campath

Campath-1H

LDP-03

LDP03

Lemtrada

MabCampath

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38908

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Alemtuzumab

Legacy Concept Name

Alemtuzumab

Maps_To

Alemtuzumab

NCI_Drug_Dictionary_ID

37783

NSC Number

715969

PDQ_Closed_Trial_Search_ID

37783

PDQ_Open_Trial_Search_ID

37783

Preferred_Name

Alemtuzumab

prefixIRI

Thesaurus:C1681

Semantic_Type

Amino Acid, Peptide, or Protein

Pharmacologic Substance

Immunologic Factor

UMLS_CUI

C0383429

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129822

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C72960

Delete Subject Author Type Created
No notes to display